ATLANTA, May 4, 2011 /PRNewswire/ -- GeoVax Labs, Inc. (OTCBB: GOVX), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, today released its 2010 Annual Report and President's Letter to the Company's stockholders. The Annual Report (10-K) provides information on the state of the Company's finances at the conclusion of 2010. In his Letter, GeoVax's President Robert T. McNally, Ph.D., provides a concise overview of the Company's Therapeutic Vaccine Program, Preventative Vaccine Program, and Financing and Corporate Development.
The 2010 Annual Report and President's Letter are available on the Company's website at www.geovax.com.
GeoVax Labs, Inc. is a biotechnology company developing human vaccines for diseases caused by HIV (Human Immunodeficiency Virus – that leads to AIDS). Our HIV/AIDS vaccine technology is exclusively licensed from Emory University in Atlanta, GA, and is the subject of more than 20 issued or filed patent applications. GeoVax's vaccines are unique in expressing virus-like particles that display the trimeric membrane bound form of the HIV-1 envelope glycoprotein. Our preventative vaccines are designed for use in uninfected people to prevent acquisition of HIV-1 and are moving forward in human clinical trials conducted by the HIV Vaccine Trials Network (HVTN). The HVTN, funded through a cooperative agreement with the NIH, is the largest worldwide clinical trials program dedicated to the development and testing of AIDS vaccines. GeoVax's vaccines also may be effective as a therapeutic treatment (for people already infected with the HIV-1 virus); a Phase 1/2 human trial for the therapeutic application of our vaccine is ongoing. Preclinical work enabling evaluation of the GeoVax DNA and MVA vaccines was funded and supported by the National Institute of Allergy and Infectious Disease (NIAID), whic
|SOURCE GeoVax Labs, Inc.|
Copyright©2010 PR Newswire.
All rights reserved